CLINICAL DECISION SUPPORT · REGISTERED WITH MEDSAFE
DNA-guided medicine at the point of care
Most medicines are prescribed without knowing the patient's genotype. XY Leap™ turns one genomic analysis into evidence-based, DNA-guided recommendations for clinicians and their patients, for life.
One analysis informs care for life
XY Leap™ Omics Platform is clinical decision support software, registered with Medsafe, New Zealand's medicines and medical devices regulator. One genomic analysis activates lifetime access, so every future prescribing decision can draw on the same result.
1,100+
guided therapeutics in total
900+
medicines with dosing guidance and phenoconversion safety checks
150
traditional medicines matched to each patient's toxicogenomic profile
75
nutraceuticals for personalized preventive and anti-inflammatory protocols
Operational today
XY Leap is built, registered with Medsafe and available to clinicians and organizations now. It is backed by a complete technical file, clinical evaluation, verification and validation, 13 years of development by a practicing clinician, and the support of clinicians and private investors.
Three ways to work with us: platform access for clinicians, providers and institutions; DNA-guided reporting at the point of care; and precision medicine education for doctors and pharmacists.
Thermo Fisher Scientific, our global strategic partner. Supported by New Zealand Trade and Enterprise (NZTE). Headquartered in Christchurch, New Zealand, serving clinicians and organizations worldwide.
Clinicians and hospitals
XY Leap gives clinicians DNA-guided prescribing support across medical and surgical specialties: dosing guidance, drug-gene interaction alerts and phenoconversion checks, alongside personalized nutrition, exercise and sleep insights. Reports update as new evidence is published. XY Leap supports, and does not replace, clinical judgment.
Pharmacies and longevity
Through pharmacies and wellness partners, XY Leap gives consumers personalized prevention and longevity insights: nutrition, exercise, sleep and environmental exposure guidance based on their own genetics, with reports that stay current as new research is published.
Workforce health
For energy, mining, agriculture and aviation, XY Leap helps occupational health teams understand how each worker's genetics may affect their response to medicines and to common workplace exposures, such as fuels, solvents, dusts and agrichemicals, and supports individualized nutrition and recovery guidance.
Defense health
For military medical teams, XY Leap supports DNA-guided prescribing alongside individualized nutrition, training and recovery guidance, helping to keep personnel healthy and ready.
Meet the Team
-
Dr Andrew Winnington
Co-founder and Chief Executive Officer
Board Director
Andrew is a NASA-trained family physician who built XY Leap over 13 years of clinical practice to bring medical genomics into everyday clinical and lifestyle decisions.
-
Craig Morris
Board Chairman and Advisor
Craig is a senior finance and governance leader from international banking and asset management, including Chief Financial Officer roles for regulated institutions in Switzerland.
-
Dr Jonathan Chen
Medical Advisory Board
Dual specialist in Intensive Care Medicine and Internal Medicine, with experience spanning preventive, primary, secondary, and tertiary healthcare. He has worked across diverse clinical and leadership settings, combining academic depth with a pragmatic and practical focus on patient-centred outcomes.
-
Dr Maneesh Deva
Medical Advisory Board
Clinical Lead Innovation, Institute of Innovation and Improvement, Te Whatu Ora Health New Zealand, Waitematā. Honorary Lecturer (Paediatrics), School of Medicine and Health Sciences, University of Auckland. General Paediatrician, Royal Australasian College of Physicians (2014). Medical Advisor Kidshealth.org.nz. Convenor NZ Paediatric Forum.
-
Dr Ben Simpson
Medical Advisory Board
Consultant Anaesthetist, Te Whatu Ora.
-
Dr Richard Goldsmith
Medical Advisory Board
FACEM with diverse clinical experience within Australasia; from large tertiary level trauma centres to sole practice in small rural towns. Also, significant prehospital and retrieval experience. Current Head of Unit at regional emergency department in South Australia.
-
“The new version is perfect compared to other pharmacogenomics tests. It was really impressive for all doctors who ordered your trials”
Dr Junichi Taguchi, MD, PhD, Chief Medical Director, Tokyo Midtown Clinic
-
“Amazing... the reports update themselves as new medical research come to light… absolutely incredible with regards to the diversity of information they give me.”
Gabe Rijpma, Former Senior Director of Health at Microsoft Asia
Bring DNA-guided decision support to your organization
We work with hospitals, clinics, pharmacy groups, employers and defense health teams. Tell us about your setting and we will show you how XY Leap fits.